Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial.

Neuro-oncology·2026
Same author

A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.

Nature genetics·2026
Same author

Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.

Neuro-oncology·2025
Same author

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.

Nature communications·2025
Same author

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.

Neuro-oncology·2024
Same author

Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype.

Genes & development·2024
Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026
Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026
Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026
Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026
Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026
Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Jul 23, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Immunotherapy for Meningiomas.

Hans-Georg Wirsching1, Michael Weller2

  • 1Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

Advances in Experimental Medicine and Biology
|July 11, 2023
PubMed
Summary
This summary is machine-generated.

Systemic immunotherapy offers new hope for meningioma patients resistant to standard treatments. Emerging strategies like immune checkpoint inhibitors and cancer vaccines show promise for controlling recurrent or advanced meningiomas.

Keywords:
Adoptive T cell therapyBiTEImmune checkpointImmune conjugateMacrophageRecurrent meningiomaVaccinationVirotherapy

More Related Videos

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.0K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Related Experiment Videos

Last Updated: Jul 23, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.0K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Meningiomas are primary brain tumors where local treatments like surgery and radiotherapy are insufficient for some patients.
  • Current systemic therapies, including chemotherapy and anti-angiogenic agents, have limited efficacy in advanced or recurrent meningiomas.
  • The success of immune checkpoint inhibitors in other advanced cancers suggests potential for immunotherapy in meningioma treatment.

Purpose of the Study:

  • To review the principles of cancer immunotherapy.
  • To summarize current clinical trials involving immunotherapy for meningioma patients.
  • To discuss the potential application of established and novel immunotherapeutic strategies for meningioma.

Main Methods:

  • Review of scientific literature on cancer immunotherapy principles.
  • Analysis of ongoing clinical trials for immunotherapy in meningioma.
  • Discussion of various immunotherapy modalities including immune checkpoint inhibitors, vaccines, cellular therapies, T cell engagers, and oncolytic virotherapy.

Main Results:

  • Classical chemotherapy and anti-angiogenic therapies show minimal activity in meningiomas.
  • Immune checkpoint inhibitors have demonstrated long-term survival benefits in other metastatic cancers.
  • A wide range of immunotherapy approaches are under investigation or in clinical use for various cancers.

Conclusions:

  • Systemic immunotherapy represents a promising avenue for meningioma patients unresponsive to local therapies.
  • Various immunotherapy strategies, including novel immune checkpoint inhibitors and therapeutic vaccines, are being explored for meningioma.
  • Further research and clinical trials are needed to establish the efficacy and applicability of these immunotherapy approaches in meningioma management.